Immunotherapy, the enlisting of the body's own immune system to more efficiently attack cancer and other diseases, has become a major point of attention all over the world as a dramatic new approach to disease treatment. It's a science that is still developing, with a growing pipeline of new immunotherapy drugs just now undergoing initial trials, but the potential is immense. Instead of blasting cancer patients with a cocktail of poisons and radiation, hurting good cells as well as bad, immunotherapy offers the hope of focusing more energy much more accurately and efficiently. The result could be a day when a whole range of cancers can be treated effectively and rapidly, with almost no negative side effects.
An example is Advaxis, a New Jersey based biotech company that is helping to lead the immunotherapy charge with a number of developing drug candidates. One of their prospects, ADXS-HPV, for use with women suffering from recurrent/refractory cervical cancer who have not had success with traditional cytotoxic therapy. The drug has been undergoing the final part of a Phase II study, and recently updated results have been extremely encouraging.
From a safety standpoint, the drug continues to be well-tolerated, a strong point of the immunotherapy approach. Similar patients undergoing chemotherapy, by comparison, virtually all have fairly severe adverse effects. In addition, the drug is showing significant efficacy in early results, with major improvements in initial survival rates. Although the final results still have to be reported, ADXS-HPV appears to be an effective weapon against cervical cancer, without the toxicity and dangerous side effects of traditional chemotherapy. With the next update due in June of 2013, a partnership of some sort is not out of the question.
For more information visit advaxis.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net